.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Chinese Patent Office
Express Scripts
Teva
Citi
US Army
US Department of Justice
Fuji
QuintilesIMS

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,399,787

« Back to Dashboard

Which drugs does patent 7,399,787 protect, and when does it expire?


Patent 7,399,787 protects ZOLINZA and is included in one NDA.

This patent has eighty-six patent family members in twenty-eight countries.

Summary for Patent: 7,399,787

Title:Methods of treating cancer with HDAC inhibitors
Abstract:The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Inventor(s): Chiao; Judy H. (Berkeley Heights, NJ), Bacopoulos; Nicholas G. (New York, NY), Miller; Thomas A. (New York, NY), Paradise; Carolyn M. (Cortland Manor, NY), Richon; Victoria M. (Rye, NY)
Assignee: Merck HDAC Research, LLC (Boston, MA)
Application Number:10/616,649
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
MerckZOLINZAvorinostatCAPSULE;ORAL021991-001Oct 6, 2006RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,399,787

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,851,509Polymorphs of suberoylanilide hydroxamic acid► Subscribe
7,148,257Methods of treating mesothelioma with suberoylanilide hydroxamic acid► Subscribe
8,067,472Methods of treating Hodgkin's and non-Hodgkin's lymphoma► Subscribe
8,101,663Polymorphs of suberoylanilide hydroxamic acid► Subscribe
7,847,122Polymorphs of suberoylanilide hydroxamic acid► Subscribe
7,652,069Polymorphs of suberoylanilide hydroxamic acid► Subscribe
7,732,490Methods of treating cancer► Subscribe
7,456,219Polymorphs of suberoylanilide hydroxamic acid► Subscribe
7,375,137Methods of treating cancer with HDAC inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,399,787

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Hong Kong1072362► Subscribe
European Patent Office2266552► Subscribe
Canada2535806► Subscribe
Canada2543319► Subscribe
Canada2632078► Subscribe
Canada2671976► Subscribe
China1720034► Subscribe
China1870985► Subscribe
China1901895► Subscribe
European Patent Office2322160► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Teva
Mallinckrodt
Merck
QuintilesIMS
Covington
Harvard Business School
Baxter
Julphar
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot